WE CLAIM: -

- 1. A method of producing a recombinant virus comprising:
 - (a) providing a viral genome;
- (b) inserting one or more first exogenous sequences encoding a desired protein or peptide into the genome;
- (c) inserting one or more second exogenous targeting sequences encoding a targeting element into the genome which has the function of targeting the complex to a specific location; and
- (d) transfecting an appropriate host, and allowing the host to produce the virus.
- 2. The method of claim 1, wherein a first exogenous sequence encodes a protein or peptide that is antigenic for the target animal.
- 3. The method of claim 1, wherein a first exogenous sequence encodes a protein or peptide that is an allergen for the target animal.
- 4. The method of claims 1-3, wherein more than one first exogenous sequence is inserted.
- 5. A recombinant virus produced by the methods of claims 1-4.
- 6. A genetic construct comprising a viral genome with a first exogenous sequence for display of a peptide or protein on a viral capsid protein, and a second exogenous sequence for display of a targeting moiety.
- 7. The construct of claim 6, wherein the viral genome is modified to attenuate the virus in its natural host organism.

- 8. The construct of claim 6, wherein the exogenous sequences are inserted into a region or regions truncated to remove sequence unnecessary for viral replication.
- 9. The construct of claim 6, wherein the viral genome has been modified or truncated.
- 10. The construct of claim 6, wherein the first exogenous sequence is antigenic in an animal.
- 11. The construct of claim 6, wherein the first exogenous sequence is allergenic in an animal.
- 12. A recombinant virus produced from the genetic construct of claim 6.
- 13. A vaccine comprising a construct of claims 6-12.
- 14. A method of using the vaccine of claim 13, comprising:
 - (a) infecting an organism with a construct of claims 6-12; and
- (b) orally feeding the whole biomass of the infected organism to human or non-human animals.
- 15. The method of claim 14, wherein the biomass has been processed for uniform dosing.
- 16. The method of claim 15, wherein the biomass is freeze dried.
- 17. The method of claim 15, wherein the biomass is encapsulated.
- 18. The vaccine of claim 13, wherein the vaccine is an oral vaccine.
- 19. The vaccine of claim 13, wherein the vaccine is an injectable vaccine.
- 20. A method of treating allergy in a subject in need of such treatment, comprising:
 - (a) providing the recombinant virus of claim 5 or claim 12; and

- (b) administering the virus to the subject.
- 21. The method of claim 20, wherein the treatment is oral.
- 22. The method of claim 20, wherein the treatment is injectable.
- 23. The method of claims 20-21, further comprising:
 - (a) infecting an organism with the recombinant virus of claim 5; and
- (b) orally feeding the whole biomass of the infected organism to human or non-human animals.
- 24. The method of claim 23, wherein the biomass has been processed for uniform dosing.
- 25. The method of claims 20-24, wherein the biomass is freeze dried.
- 26. The method of claims 20-24, wherein the biomass is encapsulated.
- 27. A method of producing a recombinant virus-like particle comprising:
 - (a) providing a viral genome;
 - (b) isolating at least one viral coat protein sequence;
- (c) inserting at least one first exogenous sequence encoding a protein or peptide of interest into the coat protein sequences;
- (d) inserting at least one second exogenous sequence encoding a targeting sequence;
- (e) cloning the viral coat protein sequence comprising the first and second exogenous sequences into an appropriate vector; and
 - (f) transforming an appropriate host.
- 28. The method of claim 27, wherein the first exogenous sequence encodes a protein or peptide that is antigenic in an animal.

- 29. The method of claim 27, wherein the first exogenous sequence encodes a protein or peptide that is an allergen in an animal.
- 30. The method of claim 27, wherein more than one first exogenous sequences is inserted.
- 31. The method of claim 27, wherein one or more of the second exogenous sequences has the function of targeting the complex to a specific location.
- 32. The method of claim 27, wherein more than one viral coat protein is isolated.
- 33. A recombinant virus-like particle produced by the method of claims 27-32.
- 34. A genetic construct comprising at least one viral coat protein containing exogenous sequence for displayed peptides or proteins.
- 35. The construct of claim 34, wherein more than one viral coat protein has been modified to display foreign proteins or peptides.
- 36. The construct of claim 34, wherein more than one non-identical exogenous protein has been inserted.
- 37. The construct of claim 34, wherein the exogenous sequence is inserted into a region truncated to remove sequence unnecessary for virus-like particle self-assembly.
- 38. The genetic construct of claim 34, wherein the first exogenous sequence is antigenic in an animal.
- 39. The genetic construct of claim 34, wherein the first exogenous sequence is allergenic in an animal.

- 40. A recombinant virus-like particle produced from the genetic construct of claims 34-39.
- 41. A method of using the recombinant virus-like particle of claims 34-39 as a vaccine, comprising:
 - (a) providing the recombinant virus-like particle; and
 - (b) administering it to a subject.
- 42. The method of claim 41, further comprising:
- (a) infecting an organism with the recombinant virus-like particle of claim 40; and
- (b) orally feeding the whole biomass of the infected organism to human or non-human animals.
- 43. The method of claim 42, wherein the biomass is processed for uniform dosing.
- 44. The method of claims 41-43, wherein the biomass is freeze dried.
- 45. The method of claims 41-43, wherein the biomass is encapsulated.
- 46. The method of claims 41-46, wherein the vaccine is used as a treatment for allergy.
- 47. The method of claim 41, wherein the vaccine is administered by injection.
- 48. A vaccine comprising the recombinant virus-like particles of claims 34-39, wherein the particles are isolated.